Takeda Pharmaceutical Co. Ltd. ADR (TAK): Price and Financial Metrics
GET POWR RATINGS... FREE!
TAK POWR Grades
- Stability is the dimension where TAK ranks best; there it ranks ahead of 98.79% of US stocks.
- TAK's strongest trending metric is Quality; it's been moving up over the last 177 days.
- TAK ranks lowest in Momentum; there it ranks in the 7th percentile.
TAK Stock Summary
- With a market capitalization of $54,514,740,859, TAKEDA PHARMACEUTICAL CO LTD has a greater market value than 96.03% of US stocks.
- Price to trailing twelve month operating cash flow for TAK is currently 0.04, higher than just 1% of US stocks with positive operating cash flow.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for TAK comes in at 1,523.46% -- higher than that of 99.65% of stocks in our set.
- Stocks that are quantitatively similar to TAK, based on their financial statements, market capitalization, and price volatility, are MELI, CTVA, STLA, PCAR, and DD.
- Visit TAK's SEC page to see the company's official filings. To visit the company's web site, go to www.takeda.com.
TAK Stock Price Chart Interactive Chart >
TAK Price/Volume Stats
| Current price | $16.41 | 52-week high | $16.58 |
| Prev. close | $16.47 | 52-week low | $12.28 |
| Day low | $16.33 | Volume | 140,169 |
| Day high | $16.44 | Avg. volume | 2,677,473 |
| 50-day MA | $15.96 | Dividend yield | 3.29% |
| 200-day MA | $14.52 | Market Cap | 51.93B |
Takeda Pharmaceutical Co. Ltd. ADR (TAK) Company Bio
The Takeda Pharmaceutical Company Limited (武田薬品工業株式会社, Takeda Yakuhin Kōgyō kabushiki gaisha) [takeꜜda jakɯçiŋ koꜜːɡʲoː] is a Japanese multinational pharmaceutical company, with partial American and British roots. It is the largest pharmaceutical company in Asia and one of the top 20 largest pharmaceutical companies in the world by revenue (top 10 following its merger with Shire). The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda. (Source:Wikipedia)
Latest TAK News From Around the Web
Below are the latest news stories about TAKEDA PHARMACEUTICAL CO LTD that investors may wish to consider to help them evaluate TAK as an investment opportunity.
BioLife Plasma Services Opens its 200th Plasma Donation Center in the U.S.BANNOCKBURN, Ill., March 27, 2023--BioLife Plasma Services, part of the global biopharmaceutical company Takeda, today announced the opening of its 200th plasma donation center in the United States (U.S.)., with new locations in West Springfield, Mass. and Pearland, Texas. This is an important milestone in BioLife’s broader expansion plans to continue opening centers in the U.S. to address the urgent and growing need for plasma. |
The Petri Dish: Takeda scores win from Nimbus licensing deal; Biogen exits partnershipTakeda paid Nimbus Therapeutics $4 billion for a psoriasis drug in December. It just met its primary goal in a midstage trial. |
Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst SaysTakeda Pharmaceutical Co Ltd (NYSE: TAK) announced results from a Phase 2b clinical trial of TAK-279 (NDI-034858) in patients with moderate-to-severe plaque psoriasis. The study met its primary and secondary endpoints, with a statistically significant greater proportion of TAK-279 patients achieving Psoriasis Area and Severity Index (PASI) 75, 90, and 100 in the 5mg, 15mg, and 30mg dosing arms compared to placebo at 12 weeks. A significantly greater proportion of TAK-279 patients achieved PASI 7 |
Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque PsoriasisOSAKA, Japan & CAMBRIDGE, Mass., March 18, 2023--Takeda (TSE:4502/NYSE:TAK) today announced positive results from a Phase 2b clinical trial of TAK-279 (NDI-034858), a highly selective, oral allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate-to-severe plaque psoriasis. The study met its primary and secondary endpoints, with a statistically significant greater proportion of TAK-279 patients achieving Psoriasis Area and Severity Index (PASI) 75, 90 and 100 in the 5mg, 15mg and |
Johnson & Johnson's Experimental Dengue Pill Shows Efficacy In Animal Studieshttps://cdn.benzinga.com/files/images/story/2023/03/15/mosquito-_image_by_shammiknr_from_pixabay.jpg?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 New data published in the journal Nature shows that Johnson & Johnson's (NYSE: JNJ) experimental dengue pill proved effective against all four virus types in mice and prevented infection from two types in monkeys. The first-in-class antiviral, shown to be safe and well tolerated in Phase 1 first-in-human clinical study, is now progressing into Phase |
TAK Price Returns
| 1-mo | 6.91% |
| 3-mo | 5.19% |
| 6-mo | 26.52% |
| 1-year | 16.12% |
| 3-year | 11.51% |
| 5-year | -26.40% |
| YTD | 5.19% |
| 2022 | 16.87% |
| 2021 | -23.58% |
| 2020 | -5.97% |
| 2019 | 19.31% |
| 2018 | -40.08% |
TAK Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Loading social stream, please wait...